These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 1380254)

  • 1. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.
    Kim KJ; Li B; Houck K; Winer J; Ferrara N
    Growth Factors; 1992; 7(1):53-64. PubMed ID: 1380254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli.
    Siemeister G; Schnurr B; Mohrs K; Schächtele C; Marmé D; Martiny-Baron G
    Biochem Biophys Res Commun; 1996 May; 222(2):249-55. PubMed ID: 8670191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation.
    Walter DH; Hink U; Asahara T; Van Belle E; Horowitz J; Tsurumi Y; Vandlen R; Heinsohn H; Keyt B; Ferrara N; Symes JF; Isner JM
    Lab Invest; 1996 Feb; 74(2):546-56. PubMed ID: 8780172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor fails to acutely modulate endothelial permeability during early angiogenesis in the chick chorioallantoic membrane.
    DeFouw LM; DeFouw DO
    Microvasc Res; 2000 Nov; 60(3):212-21. PubMed ID: 11078637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
    Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
    Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor.
    Basu S; Nagy JA; Pal S; Vasile E; Eckelhoefer IA; Bliss VS; Manseau EJ; Dasgupta PS; Dvorak HF; Mukhopadhyay D
    Nat Med; 2001 May; 7(5):569-74. PubMed ID: 11329058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
    Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
    Partanen TA; Paavonen K
    Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor-induced migration of vascular smooth muscle cells in vitro.
    Grosskreutz CL; Anand-Apte B; Dupláa C; Quinn TP; Terman BI; Zetter B; D'Amore PA
    Microvasc Res; 1999 Sep; 58(2):128-36. PubMed ID: 10458928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
    Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo.
    Soh EY; Eigelberger MS; Kim KJ; Wong MG; Young DM; Clark OH; Duh QY
    Surgery; 2000 Dec; 128(6):1059-65;discussion 1065-6. PubMed ID: 11114643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A potential autocrine role for vascular endothelial growth factor in prostate cancer.
    Jackson MW; Roberts JS; Heckford SE; Ricciardelli C; Stahl J; Choong C; Horsfall DJ; Tilley WD
    Cancer Res; 2002 Feb; 62(3):854-9. PubMed ID: 11830543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
    Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
    Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions.
    Yamagishi S; Yonekura H; Yamamoto Y; Fujimori H; Sakurai S; Tanaka N; Yamamoto H
    Lab Invest; 1999 Apr; 79(4):501-9. PubMed ID: 10212003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.